Navigation Links
Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008
Date:11/6/2008

primarily from the Company's recognition of deferred tax assets as it transitions to a fully taxed rate. Diluted EPS was $1.48 for the first nine months of the year, including a $0.33 net benefit resulting primarily from the one-time recognition of deferred tax assets, based on 17.6 million weighted average common shares outstanding.

The Company completed its IPO on November 2, 2007. On a pro forma basis, assuming conversion of all outstanding preferred stock, diluted EPS for the three and nine months ended September 30, 2007 would have been $0.28 and $0.68, respectively (see "Pro Forma Net Income Per Share" table below).

Gross profit for the third quarter of 2008 was $19.8 million, up from $9.7 million for the third quarter of 2007, or 62% as compared to 60%, respectively. The benefit from changes in accounting estimates added approximately 3% to the gross margin for the third quarter. For the first nine months of 2008, gross profits totaled $49.5 million, compared to $24.2 million for the same period in 2007, with gross profit of approximately 60% for the first nine months of 2008, consistent with the prior year period.

Operating expenses for the third quarter of 2008 increased to $11.2 million from $6.0 million for the third quarter of 2007, and to $31.6 million for the first nine months of 2008 from $15.3 million during the same period in 2007. These expenses were higher primarily due to investment in additional personnel to support revenue growth, stock-based compensation expense and the increased costs associated with operating as a public company. Operating income for the third quarter of 2008 was $8.6 million, compared to $3.7 million during the same period in 2007. Operating income was $17.9 million for the first nine months of 2008, up from $8.9 million for the first nine months of 2007.

As of September 30, 2008, the Company's total cash and investments were $101.3 million, of which $4.1 million was classified as long-term. For
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Genoptix, Inc. Announces Pricing for Initial Public Offering
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
4. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
5. Genoptix Announces Pricing of Secondary Public Offering
6. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
7. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
8. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
9. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
10. Genoptix Reports Strong Financial Results for First Quarter 2008
11. Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... The first federal bellwether trial of ... third week in the U.S. District Court, Northern District ... indicate that the week opened in the DePuy ... DePuy Orthopaedics vice president, who discussed the clinical testing ... hip replacement. According to Reuters, the executive stated that ...
(Date:9/20/2014)... Nevada (PRWEB) September 20, 2014 ... extremely successful showing at the PAIN Week conference ... Cosmopolitan Hotel and Casino in Las Vegas from ... MarijuanaDoctors.com primarily attended PAIN Week in the hopes ... as a viable and legitimate tool to treat ...
(Date:9/19/2014)... (PRWEB) September 20, 2014 Nearly 780 ... of Common Pleas where a meeting took place to ... complaints pending in the court’s mass tort program. ... meet this past week at the Complex Litigation Center ... consolidated for pretrial proceedings. The Risperdal lawsuits filed against ...
(Date:9/19/2014)... DC) (PRWEB) September 19, 2014 “Copay ... inflate sales of brand drugs among patients with prescription ... according to a new report from the ... Inspector General (OIG). Federal anti-kickback laws prohibit suppliers from ... subsidized by the federal government. , The report highlights ...
(Date:9/19/2014)... September 19, 2014 Unbound , an ... families in regions of the Philippines being affected by both ... than 1,060 families evacuated to the nearest public schools while ... heavy rain and gusty winds to portions of the northern ... flooding. Some homes filled with more than 10 feet of ...
Breaking Medicine News(10 mins):Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2
... egg should be avoided by patients with high cholesterol ... has developed a egg variety that does no ... diabetes is growing especially in Indian sub-continent. 'The modified ... S.K. Taneja, a professor in the university's Department of ...
... are increasingly recognized as important factors in disease ... drug resistance. However, the distinction of co-infecting site ... been // ficult with traditional methods based on ... ,Trypanosoma brucei , a protozoan parasite transmitted by ...
... can be used to reveal the strength of bones ... the likelihood of fracturing a particular bone, an article ... says. ,Scientists have developed a laser imaging technique ... density thereby predicting future risk of fracturing that particular ...
... from Italy have found a new urine test which detects ... test which is proved to be 90% accurate is used ... of patients. The results of the study have been published ... would be very useful for detecting cancer in smokers and ...
... perception is dependent on the specialized cells of the eye. ... a research state that our perception of color is controlled ... ,The number of color-sensitive cones in the human retina differs ... perceive colors the same way. The study has shown that ...
... In a novel initiative to combat the spread of ... joint initiative// of the William J. Clinton Foundation and ... entered into a partnership with Nickelodeon's award-winning Let's Just ... forces on a comprehensive media and public awareness campaign, ...
Cached Medicine News:Health News:Fluorescent markers to distinguish Trypanosoma brucei strains causing Sleeping Sickness 2Health News:Urine testing for telomerase enzyme for bladder cancer diagnosis 2Health News:Seeing Is Believing Does Not Hold Good For Color Perception 2Health News:A New Initiative To Fight Childhood Obesity 2
(Date:9/19/2014)... Sept. 19, 2014  Pressure BioSciences, Inc. (OTCQB: ... has received and approved all parts required to ... has begun to manufacture the new PCT-based instrument ... be ready for shipment by mid-October and that ... at a rate of about one per week ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
(Date:9/19/2014)... -- PCI is pleased to announce it has acquired ... provider of Clinical Trial Services and Temperature Controlled ... in the United Kingdom ... in the UK/EU to support global investigational studies ... distribution capacity, as well as consultative services for ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
2 mm wide x 3 mm long, tapered handle. Angled 45 degrees. Round handle....
1.5 mm long blade. Square handle....
3 mm diameter roller blade in line with handle. Curved shaft. Flat handle. 15 mm from curve to tip....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Medicine Products: